American Heart Association In Brief
This article was originally published in The Gray Sheet
Executive Summary
Study results on ICD programming, biventricular pacing and more from the 2012 AHA Scientific Sessions in Los Angeles.
You may also be interested in...
FDA Approves Medtronic’s CRT Devices For Less Severe Heart Failure
Following the advice of its advisory panel, FDA expanded the indication for two Medtronic cardiac resynchronization pacemakers and eight cardiac resynchronization defibrillators to include patients with atrioventricular block and less severe heart failure.
FDA Panel Narrowly Favors Expanding Patient Population For Biventricular Pacing
With the help of a tie-breaker vote, the Circulatory System Devices Advisory Panel said the benefits outweigh the risks of expanding the indications for biventricular cardiac resynchronization therapy devices to include patients at risk for developing new or worsened heart failure because of their need for right ventricular pacing. Medtronic is seeking the expansion in a submission before FDA.
FDA Panel Narrowly Favors Expanding Patient Population For Biventricular Pacing
With the help of a tie-breaker vote, the Circulatory System Devices Panel said the benefits outweigh the risks of expanding the indications for biventricular cardiac resynchronization therapy devices to include patients at risk for developing new or worsened heart failure because of their need for right ventricular pacing. Medtronic is seeking the expansion in a submission before FDA.